Obesity Surgery

, Volume 18, Issue 10, pp 1211–1214

Surgery for Diabetes at Lower BMI: Some Caution

Editorial

Keywords

Diabetes mellitus Bariatric surgery GLP-1 Insulin resistance C-peptide BMI 

References

  1. 1.
    Deitel M. The obesity epidemic (editorial). Obes Surg. 2006;16:377–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Eades MR, Eades MD. Protein Power. New York: Bantam, 1996 (ISBN 0553574752).Google Scholar
  3. 3.
    Brody H. The other side of Eden: hunter–gatherers, farmers and the shaping of the world. UK: Faber & Faber, 2002 (ISBN 10:057120502X).Google Scholar
  4. 4.
    Jenkins DJ, Wolever TM, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34:362–6.PubMedGoogle Scholar
  5. 5.
    Jenkins DJ, Kendall CW, Augustin LS, et al. Glycemic index: overview of implications in health and disease. Am J Clin Nutr 2002;76:266S–73S.PubMedGoogle Scholar
  6. 6.
    Baier LJ, Hanson RL. Genetic studies of the etiology of type 2 diabetes in Pima Indians. Diabetes. 2004;53:1181–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Reaven GM. The individual components of the metabolic syndrome: is there a raison d’etre? J Am Coll Nutr 2007;26:191–5.PubMedGoogle Scholar
  8. 8.
    Sanderson I, Deitel M. Insulin response in patients receiving concentrated infusions of glucose and casein hydrolysate for complete parenteral nutrition. Ann Surg. 1974;179:387–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Gumbs AA, Modlin AM, Ballantyne GH. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg. 2005;15:462–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Wickremesekera K, Millor G, Naotunne TD, et al. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg. 2005;15:474–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Sanderson I, Deitel M, Bojm MA. The handling of glucose and insulin response before and after weight loss with jejuno-ileal bypass: a preliminary report. JPEN 1983;7:274–6.Google Scholar
  12. 12.
    Deitel M, Sidhu PS, Stone E. Effect of vertical banded gastroplasty on diabetes in the morbidly obese. Obes Surg 1991;1:113–4. (abstr).Google Scholar
  13. 13.
    Keith SH, Mason EE, Scott DH, et al. Serum insulin and glucose levels, and insulin binding kinectics, in morbid and super obese patients undergoing vertical banded gastroplasty. Obes Surg. 1991;1:112. (abstr).Google Scholar
  14. 14.
    Smith SG, Edwards CB, Goodman GM. Changes in diabetic management after Roux-en-Y gastric bypass. Obes Surg. 1996;6:345–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Halverson JD, Kramer J, Cave A, et al. Altered glucose tolerance, insulin response, and insulin sensitivity after massive weight reduction subsequent to gastric bypass. Surgery. 1982;92:235–40.PubMedGoogle Scholar
  16. 16.
    Deitel M. The early effect of bariatric operations on diabetes (commentary). Obes Surg. 2002;12:349.PubMedCrossRefGoogle Scholar
  17. 17.
    Dixon JB, Dixon AF, O’Brien PE. Improvement in insulin sensitivity and beta cell function (HOMA) with weight loss in the severely obese. Homeostatic model assessment. Diab Med. 2003;20:127–34.CrossRefGoogle Scholar
  18. 18.
    Burstein R, Epstein Y, Charuzi I, et al. Glucose utilization in morbidly obese subjects before and after weight loss by gastric bypass operation. Int J Obes. 1995;19:558–61.Google Scholar
  19. 19.
    Pories WJ. Why does the gastric bypass control type 2 diabetes mellitus? Obes Surg. 1992;2:303–13.PubMedCrossRefGoogle Scholar
  20. 20.
    Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Lamounier RN, Pareja JC, Tambascia MA, et al. Incretins: clinical physiology and bariatric surgery—correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure. Obes Surg. 2007;17:569–76.PubMedCrossRefGoogle Scholar
  22. 22.
    Näslund E, Backman L, Holst JJ, et al. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg. 1998;8:253–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Mason EE. Gastric emptying controls type 2 diabetes mellitus (editorial). Obes Surg. 2007;17:853–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Valverde I, Puente J, Martin-Duce A, et al. Changes in glucagons-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg. 2005;15:387–97.PubMedCrossRefGoogle Scholar
  25. 25.
    Livingston EH. Lowering the bariatric surgery minimum body mass index threshold. Arch Surg. 2008;143:708–10.PubMedCrossRefGoogle Scholar
  26. 26.
    Cohen RV, Schiavon GA, Pinheiro JC, et al. Duodenal–jejunal bypass for the treatment of type 2 diabetes in patients with BMI 22-34: a report of 2 cases. Surg Obes Relat Dis. 2007;3:195–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Scopinaro N, Papadia F, Marinari G, et al. Long-term control of type 2 diabetes mellitus and the other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI <35 kg/m2. Obes Surg. 2007;17:185–92.PubMedCrossRefGoogle Scholar
  28. 28.
    Melissas J, Daskalakis M, Koukouraki S, et al. Sleeve gastrectomy—a “food limiting” operation. Obes Surg. 2008;18:Oct (in press).Google Scholar
  29. 29.
    Frühbeck G, Diez-Caballero A, Gil MJ, et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg. 2004;14:606–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Mason EE. Ileal transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Obes Surg. 1999;9:223–8.PubMedCrossRefGoogle Scholar
  31. 31.
    DePaula AL, Macedo ALV, Rossi N, et al. Laparoscopic treatment of type 2 diabetes mellitus for patients with body mass index less than 35. Surg Endosc. 2008;22:706–16.PubMedCrossRefGoogle Scholar
  32. 32.
    Zimmet P, Turner R, McCarty D, et al. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diab Care. 1999;22:B59–64.Google Scholar
  33. 33.
    Landin-Olsson M. Latent autoimmune diabetes in adults. Ann NY Acad Sci. 2002;958:112–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Seisser J. Latent (slowly progressing) autoimmune diabetes in adults. Curr Diab Rep. 2008;8:94–100.CrossRefGoogle Scholar
  35. 35.
    Brophy S, Yderstraede K, Mauricio D, et al. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diab Care. 2008;31:439–41.CrossRefGoogle Scholar
  36. 36.
    Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitor in type 2 diabetes. Lancet. 2006;368(9548):1696–705.PubMedCrossRefGoogle Scholar
  37. 37.
    Madsbad S, Krarup T, Deacon CF, et al. Glucagon-like peptide receptor agonists and dipeptyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care. 2008;11:491–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  1. 1.Editor-in-ChiefObesity SurgeryTorontoCanada
  2. 2.TorontoCanada

Personalised recommendations